PolyVation is proud to announce that the first clinical product enabled by SynBiosys™ multi-block copolymers has received regulatory approval. SynBiosys™ makes part of the Combo Dual Therapy Stent of OrbusNeich to control drug release from the metal stent surface. The Combo stent received a CE Mark allowing a sales roll-out in Europe and selected markets in the Asia Pacific and Middle East regions.
The key opinion leader in the field of drug eluting stents, Renu Virmani,M.D., commented that the Combo stent is the only stent with full and complete polymer degradation within 90 days, affording it the safety profile of a bare metal stent with the added benefit of allowing healing while suppressing smooth muscle cell proliferation.
SynBiosys™ is a unique family of highly innovative bioresorbable multi-block copolymers. The philosophy behind our patented SynBiosys polymer concept is full control of chemical-physical properties in an optimal balance to each other.
SynBiosys™ is explored and exploited by InnoCore Pharmaceuticals, a polymer technology subsidiary of PolyVation.
*SynBiosys™ is a trade mark of InnoCore Pharmaceuticals and Combo Dual Therapy Stent is a trade mark of OrbusNeich.